Medication-induced osteoporosis: screening and treatment strategies
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Drug-induced osteoporosis is a significant health problem and many physicians are unaware that many commonly prescribed medications contribute to significant bone loss and fractures. In addition to glucocorticoids, proton pump inhibitors, selective serotonin receptor inhibitors, thiazolidinediones, anticonvulsants, medroxyprogesterone acetate, aromatase inhibitors, androgen deprivation therapy, heparin, calcineurin inhibitors, and some chemotherapies have deleterious effects on bone health. Furthermore, many patients are treated with combinations of these medications, possibly compounding the harmful effects of these drugs. Increasing physician awareness of these side effects will allow for monitoring of bone health and therapeutic interventions to prevent or treat drug-induced osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071408 · Cited by 914
Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11283 · Cited by 559
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Use of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529
Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60250-6 · Cited by 527
Scholes, D., LaCroix, A. Z., Ichikawa, L. E., Barlow, W. E., & Ott, S. M. (2005) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.159.2.139 · Cited by 221
Glucocorticoids and the regulation of growth hormone secretion
Mazziotti, G., & Giustina, A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.5 · Cited by 206
Smith, M. R., Goode, M., Zietman, A. L., McGovern, F. J., Lee, H., & Finkelstein, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.174 · Cited by 188
Injectable Hormone Contraception and Bone Density: Results from a Prospective Study
Scholes, D., LaCroix, A. Z., Ichikawa, L. E., Barlow, W. E., & Ott, S. M. (2002) · Epidemiology · doi:10.1097/00001648-200209000-00015 · Cited by 187
Glucocorticoids and bone: Local effects and systemic implications
Henneicke, H., Gasparini, S. J., Brennan-Speranza, T. C., Zhou, H., & Seibel, M. J. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.006 · Cited by 168
Warfarin Use and Risk for Osteoporosis in Elderly Women
Jamal, S. A., Browner, W. S., Bauer, D. C., & Cummings, S. R. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-10-199805150-00006 · Cited by 153
Osteocalcin. Biochemical considerations and clinical applications
LIAN, J. B., & GUNDBERG, C. M. (1988) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198801000-00036 · Cited by 149
Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate
Clark, M. K., Sowers, M. R., Nichols, S., & Levy, B. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.04.064 · Cited by 126 · cited 1×
“Bone loss appears to decline rapidly in the first 2 years of treatment followed by a plateau [Cromer et al. 2008; Scholes et al. 2002; Clark et al. 2004].”
BackgroundEom, C.-S., Lee, H.-K., Ye, S., Park, S. M., & Cho, K.-H. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1554 · Cited by 123
WHO statement on hormonal contraception and bone health
d'Arcangues, C. (2006) · Contraception · doi:10.1016/j.contraception.2006.01.002 · Cited by 109
Use of Depot Medroxyprogesterone Acetate and Fracture Risk
Meier, C., Brauchli, Y. B., Jick, S. S., Kraenzlin, M. E., & Meier, C. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0032 · Cited by 90 · cited 13×
“Studies have shown that prescribing low-dose estrogen replacement to DMPA users can prevent bone loss in premenopausal women on DMPA [Cundy et al.”
BackgroundInfluentialBone density changes in pregnant women treated with heparin: a prospective, longitudinal study
Backos, M., Rai, R., Thomas, E., Murphy, M., Doré, C., & Regan, L. (1999) · Human Reproduction · doi:10.1093/humrep/14.11.2876 · Cited by 84
Use of Depot Medroxyprogesterone Acetate Contraception and Incidence of Bone Fracture
Lanza, L. L., McQuay, L. J., Rothman, K. J., Bone, H. G., Kaunitz, A. M., Harel, Z., Ataher, Q., Ross, D., Arena, P. L., & Wolter, K. D. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318283d1a1 · Cited by 78 · cited 1×
“23) did not significantly increase as a result of DMPA use [Lanza et al. 2013].”
BackgroundMitwally, M. F. M., Gotlieb, L., & Casper, R. F. (2002) · Menopause · doi:10.1097/00042192-200207000-00004 · Cited by 53
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2008) · Contraception · doi:10.1016/j.contraception.2008.07.014 · Cited by 51
Zawawi, M. S. F., Dharmapatni, A. A. S. S. K., Cantley, M. D., McHugh, K. P., Haynes, D. R., & Crotti, T. N. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.09.077 · Cited by 29
Cited by
Glucocorticoid-Induced Osteoporosis
Buckley, L., & Humphrey, M. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1800214 · Cited by 438
Self-citationHarvey, N. C. W., McCloskey, E. V., Mitchell, P. J., Dawson-Hughes, B., Pierroz, D. D., Reginster, J.-Y., Rizzoli, R., Cooper, C., & Kanis, J. A. (2017) · Osteoporosis International · doi:10.1007/s00198-016-3894-y · Cited by 227
Coluzzi, F., Mattia, C., Raffa, R. R., & Pergolizzi, J. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s79409 · Cited by 77
“Chronic use of these medications increases the risk of reduced bone mineral density (BMD) and fractures, particularly when patients are polymedicated with more than one of these drugs.(23) Opioids have been recognized as a risk factor for the development of osteoporosis for more than 10 years.”
BackgroundManuylova, E., Calvi, L. M., Vates, G. E., Hastings, C., & Shafiq, I. (2015) · Endocrine Practice · doi:10.4158/ep15652.or · Cited by 16
Metadata
- Authors
- Panday, K., Gona, A., & Humphrey, M. B.
- Venue
- Therapeutic Advances in Musculoskeletal Disease
- Publisher
- SAGE Publications
- Published
- 2014-08-11
- Volume
- 6
- Issue
- 5
- Pages
- 185-202
- ISSN
- 1759-720X (ISSN-L)
- 1759-7218
- OpenAlex
- W2005836587
- Cited by
- 201
- References
- 25
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.